Every material Form 8-K Aurinia Pharmaceuticals Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aurinia reported third-quarter 2026 total revenue of $83.7 million, up 14% from a year earlier, while net income and diluted earnings per share were flat at $31.7 million and $0.23. The company raised its 2026 total revenue guidance to $325 million to $330 million and narrowed its net product sales guidance to $310 million to $315 million.
Q3 2026 total revenue was $83.7 million, up 14% from $73.5 million; net product sales of LUPKYNIS were $79.4 million.
Q3 net income was $31.7 million, flat year over year; nine-month net income rose 35% to $103.5 million.
2026 total revenue guidance raised from $315 million-$325 million to $325 million-$330 million.
As of September 30, 2026, cash, cash equivalents, restricted cash and investments totaled $486.9 million.
Aurinia Pharmaceuticals said it has settled patent infringement litigation with Teva Pharmaceuticals over Teva's application to sell a generic 7.9 mg voclosporin capsule in the United States. Under the settlement, Teva has stipulated that Aurinia's two U.S. patents are enforceable, valid and would be infringed, and Teva may launch no earlier than December 7, 2036, subject to earlier contingencies and FDA approval. The filing gives no financial figures, and Aurinia's other patent actions continue.
Teva stipulated that U.S. Patent Nos. 10,286,036 and 11,622,991 are enforceable, valid and would be infringed, and that the patents expire in December 2037.
Teva may launch its generic voclosporin no earlier than December 7, 2036, unless defined contingencies occur earlier.
Teva's U.S. launch also depends on FDA approval of its generic product.
Aurinia's patent infringement actions against five other companies continue in the U.S. District Court for the District of New Jersey.
Aurinia reported second-quarter 2026 total revenue of $83.2 million, up 19% from a year earlier, with net income of $37.4 million and diluted EPS of $0.28, both up sharply from the prior-year quarter. The company reiterated its 2026 total revenue guidance of $315 million to $325 million, so the headline results improved and the outlook was unchanged.
Q2 2026 total revenue was $83.2 million, up 19% from $70.0 million; net product sales of LUPKYNIS were $79.4 million.
Q2 2026 net income was $37.4 million, up 74% from $21.5 million; diluted EPS was $0.28 versus $0.16.
2026 guidance reiterated: total revenue of $315 million to $325 million and net product sales of $305 million to $315 million.
In the six months ended June 30, 2026, Aurinia repurchased 5.0 million common shares for $74.9 million; cash and investments were $443.1 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aurinia Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →